np137
mAbexperimental
Clinical trial activity
7 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 9, 2017 (NCT02977195)
Timeline
Indications
Mechanism of action
- Netrin-1INHIBITOR
NTN1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- np137
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06203821 | Phase 1 | Jan 1, 2025 | NETRIS Pharma, University of Rochester |
| NCT06150040 | Phase 1/Phase 2 (Phase 2) | Dec 4, 2023 | Centre Leon Berard, NETRIS Pharma |
| NCT05546879 | Phase 1 | Nov 30, 2022 | NETRIS Pharma, University of Grenoble |
| NCT05546853 | Phase 1 | Nov 30, 2022 | NETRIS Pharma, University of Grenoble |
| NCT05605496 | Phase 2 | Nov 24, 2022 | Centre Leon Berard, NETRIS Pharma |
| NCT04652076 | Phase 1/Phase 2 (Phase 2) | Nov 25, 2020 | Centre Leon Berard, Merck, NETRIS Pharma |
| NCT02977195 | Phase 1 | Jan 9, 2017 | Centre Leon Berard, NETRIS Pharma |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NETRIS Pharma | For profit | 7 | 1 | 2 | 2017 |
| Centre Leon Berard | Academic/Hospital | 4 | 3 | 2 | 2017 |
| University of Grenoble | Academic/Hospital | 2 | 2 | 1 | 2022 |
| Merck | For profit | 1 | 0 | 1 | 2020 |
| University of Rochester | Academic/Hospital | 1 | 1 | 1 | 2025 |
5 organizations
Page 1 / 1